Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Seres Therapeutics ( (MCRB) ) is now available.
On July 17, 2025, Seres Therapeutics announced the resignation of Eric D. Shaff from his roles as President and CEO, effective July 31, 2025, though he will remain on the Board of Directors. The company has appointed Marella Thorell and Thomas J. DesRosier as Co-Chief Executive Officers and Co-Presidents, effective August 1, 2025, to ensure a smooth transition. This leadership change is accompanied by financial arrangements, including bonuses for the new appointees, reflecting the company’s strategic focus on maintaining stability and continuity during this transition.
The most recent analyst rating on (MCRB) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Seres Therapeutics stock, see the MCRB Stock Forecast page.
Spark’s Take on MCRB Stock
According to Spark, TipRanks’ AI Analyst, MCRB is a Neutral.
Seres Therapeutics’ overall score reflects significant financial challenges with unstable revenue, high debt, and negative cash flows. Technical indicators suggest bearish momentum, while valuation is affected by negative earnings. The earnings call provided some optimism with SER-155 progress and financial improvements, but uncertainties remain. Overall, the stock score indicates caution due to financial instability and bearish technical trends.
To see Spark’s full report on MCRB stock, click here.
More about Seres Therapeutics
Seres Therapeutics operates in the biotechnology industry, focusing on developing microbiome therapeutics to treat diseases by modulating the composition of the microbiome.
Average Trading Volume: 120,526
Technical Sentiment Signal: Sell
Current Market Cap: $122.9M
Find detailed analytics on MCRB stock on TipRanks’ Stock Analysis page.